首页 > 最新文献

Allergy, Asthma & Immunology Research最新文献

英文 中文
Bacterial Etiology in Subacute Cough. 亚急性咳嗽的细菌病原学。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-09-01 Epub Date: 2023-04-26 DOI: 10.4168/aair.2023.15.5.673
Ji-Yong Moon, Hyun Lee, Min-Hye Kim, Woo-Jung Song, Sang Min Lee, Sae-Hoon Kim, Sang-Heon Kim, Byung-Jae Lee, Ho Joo Yoon, Sang Hoon Kim

Although postinfectious etiology is the most common cause of subacute cough, there are insufficient data on the epidemiology of associated bacterial infections. We aimed to identify the etiology of bacterial detection in subjects with subacute cough. A multicenter prospective observational study of 142 patients with postinfectious subacute cough was performed between August 2016 and December 2017 in Korea. We obtained 2 nasal swabs from each patient and used a multiplex bacterial polymerase chain reaction (PCR) kit that simultaneously detects Bordetella pertussis, Chlamydophila pneumoniae, Haemophilus influenzae, Legionella pneumophilia, Mycoplasma pneumoniae, and Streptococcus pneumoniae. About 29% (n = 41) of patients with subacute cough were positive for bacterial PCR in nasal swabs. The most common bacteria detected by bacterial PCR was H. influenzae (n = 19, 13.4%), followed by S. pneumoniae (n = 18, 12.7%), B. pertussis (n = 7, 4.9%), M. pneumoniae (n = 3, 2.1%), L. pneumophilia (n = 2, 1.4%), and C. pneumoniae (n = 1, 0.7%). Nine patients had dual positivity for the PCR. In conclusion, bacterial PCR was positive in the nasal swabs of about 29% of subjects with subacute cough, including 5% of positive PCR results for B. pertussis.

尽管感染后病因是亚急性咳嗽最常见的原因,但相关细菌感染的流行病学数据不足。我们旨在确定亚急性咳嗽受试者细菌检测的病因。2016年8月至2017年12月,在韩国对142名感染后亚急性咳嗽患者进行了一项多中心前瞻性观察性研究。我们从每位患者身上获得了2个鼻拭子,并使用多重细菌聚合酶链式反应(PCR)试剂盒同时检测百日咳杆菌、肺炎衣原体、流感嗜血杆菌、嗜肺军团菌、肺炎支原体和肺炎链球菌。约29%(n=41)的亚急性咳嗽患者的鼻拭子细菌聚合酶链式反应呈阳性。细菌聚合酶链式反应检测到的最常见细菌是流感嗜血杆菌(n=19,13.4%),其次是肺炎链球菌(n=18,12.7%)、百日咳杆菌(n=7,4.9%)、肺炎支原体(n=3,2.1%)、嗜肺乳杆菌(n=2,1.4%)和肺炎克雷伯菌(n=1,0.7%)。9名患者的聚合酶链式反应呈双重阳性。总之,约29%的亚急性咳嗽受试者的鼻拭子中细菌聚合酶链式反应呈阳性,其中5%的百日咳杆菌聚合酶链式反应阳性。
{"title":"Bacterial Etiology in Subacute Cough.","authors":"Ji-Yong Moon,&nbsp;Hyun Lee,&nbsp;Min-Hye Kim,&nbsp;Woo-Jung Song,&nbsp;Sang Min Lee,&nbsp;Sae-Hoon Kim,&nbsp;Sang-Heon Kim,&nbsp;Byung-Jae Lee,&nbsp;Ho Joo Yoon,&nbsp;Sang Hoon Kim","doi":"10.4168/aair.2023.15.5.673","DOIUrl":"https://doi.org/10.4168/aair.2023.15.5.673","url":null,"abstract":"<p><p>Although postinfectious etiology is the most common cause of subacute cough, there are insufficient data on the epidemiology of associated bacterial infections. We aimed to identify the etiology of bacterial detection in subjects with subacute cough. A multicenter prospective observational study of 142 patients with postinfectious subacute cough was performed between August 2016 and December 2017 in Korea. We obtained 2 nasal swabs from each patient and used a multiplex bacterial polymerase chain reaction (PCR) kit that simultaneously detects <i>Bordetella pertussis</i>, <i>Chlamydophila pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>Legionella pneumophilia</i>, <i>Mycoplasma pneumoniae</i>, and <i>Streptococcus pneumoniae</i>. About 29% (n = 41) of patients with subacute cough were positive for bacterial PCR in nasal swabs. The most common bacteria detected by bacterial PCR was <i>H. influenzae</i> (n = 19, 13.4%), followed by <i>S. pneumoniae</i> (n = 18, 12.7%), <i>B. pertussis</i> (n = 7, 4.9%), <i>M. pneumoniae</i> (n = 3, 2.1%), <i>L. pneumophilia</i> (n = 2, 1.4%), and <i>C. pneumoniae</i> (n = 1, 0.7%). Nine patients had dual positivity for the PCR. In conclusion, bacterial PCR was positive in the nasal swabs of about 29% of subjects with subacute cough, including 5% of positive PCR results for <i>B. pertussis.</i></p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 5","pages":"673-681"},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/6c/aair-15-673.PMC10570775.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41188242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunonutrition: Diet Diversity, Gut Microbiome and Prevention of Allergic Diseases. 免疫营养:饮食多样性、肠道微生物组和过敏性疾病的预防。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-09-01 DOI: 10.4168/aair.2023.15.5.545
Carina Venter

Allergic diseases are increasing both in morbidity and mortality. Genetic, environmental, and dietary factors may all be involved in this increase. Nutrition during pregnancy, breastfeeding, and early life may play a particularly important role in preventing allergic diseases. Based on current systematic reviews, the intake of specific nutrients has failed to prevent allergic disease. Prevention strategies have shifted their focus to the overall diet which can be described using diet diversity. Infant and maternal diet diversity in pregnancy has been associated with reduced allergy outcomes in childhood. Overall, diet also seems to have a marked effect on the microbiome compared to single foods. Factors that may negate the allergy-preventative effect of overall diet diversity include the addition of emulsifiers, advanced glycation end-product content, and overuse of commercial baby foods. There is a need to perform randomized controlled trials using overall dietary intake to support international food allergy guidelines. These studies should ideally be conducted by multi-professional teams.

过敏性疾病的发病率和死亡率都在增加。遗传、环境和饮食因素可能都与这种增长有关。怀孕、母乳喂养和早期生活中的营养可能在预防过敏性疾病方面发挥特别重要的作用。根据目前的系统综述,摄入特定营养素未能预防过敏性疾病。预防策略已经将重点转移到整体饮食上,这可以用饮食多样性来描述。婴儿和母亲在妊娠期的饮食多样性与儿童期过敏反应的减少有关。总的来说,与单一食物相比,饮食似乎对微生物组也有显著影响。可能否定整体饮食多样性的过敏预防作用的因素包括添加乳化剂、晚期糖化终产物含量和过度使用商业婴儿食品。有必要使用总体饮食摄入量进行随机对照试验,以支持国际食品过敏指南。这些研究最好由多专业团队进行。
{"title":"Immunonutrition: Diet Diversity, Gut Microbiome and Prevention of Allergic Diseases.","authors":"Carina Venter","doi":"10.4168/aair.2023.15.5.545","DOIUrl":"10.4168/aair.2023.15.5.545","url":null,"abstract":"<p><p>Allergic diseases are increasing both in morbidity and mortality. Genetic, environmental, and dietary factors may all be involved in this increase. Nutrition during pregnancy, breastfeeding, and early life may play a particularly important role in preventing allergic diseases. Based on current systematic reviews, the intake of specific nutrients has failed to prevent allergic disease. Prevention strategies have shifted their focus to the overall diet which can be described using diet diversity. Infant and maternal diet diversity in pregnancy has been associated with reduced allergy outcomes in childhood. Overall, diet also seems to have a marked effect on the microbiome compared to single foods. Factors that may negate the allergy-preventative effect of overall diet diversity include the addition of emulsifiers, advanced glycation end-product content, and overuse of commercial baby foods. There is a need to perform randomized controlled trials using overall dietary intake to support international food allergy guidelines. These studies should ideally be conducted by multi-professional teams.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 5","pages":"545-561"},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c5/83/aair-15-545.PMC10570780.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41188247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
TRIM24-Mediated Acetylation of STAT6 Suppresses Th2-Induced Allergic Rhinitis. TRIM24介导的STAT6乙酰化抑制Th2诱导的过敏性鼻炎。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-09-01 DOI: 10.4168/aair.2023.15.5.603
Liyan Yue, Qiaojing Jia, Jinhui Dong, Jianxing Wang, Xiumin Ren, Ou Xu

Purpose: Allergic rhinitis (AR) is a T helper type 2 (Th2)-mediated inflammatory disease. The E3 ligase tripartite motif-containing 24 (TRIM24) regulates the recruitment of acetyltransferase CREB-binding protein (CBP) to signal transducer and activator of transcription 6 (STAT6). CBP mediates the acetylation of STAT6 and decreases its activity. To date, the precise role of TRIM24 in AR has not been fully interpreted. Herein, our study aimed to explore the functions of TRIM24 in AR.

Methods: The expression of TRIM24 in peripheral blood mononuclear cells (PBMCs) and CD4+ T cells from patients with AR was measured. TRIM24-conditional knockout mice with TRIM24 deficiency in CD4+ T cells were generated. Wide-type (WT) AR mice and TRIM24-conditional knockout AR mice were established. Then, AR symptoms and interleukin (IL)-4 levels were compared. Further, the proliferation, activation and polarization of CD4+ T cells from WT mice and TRIM24 knockout mice after stimulation were determined. The effects of TRIM24 deficiency on STAT6 activities were also evaluated.

Results: Downregulated TRIM24 expression was detected in PBMCs and CD4+ T cells from patients with AR. TRIM24 conditional knockout mice had more sever AR symptoms with elevated IL-4 production. TRIM24-knockout CD4+ T cells had similar proliferation and activation when compared to WT CD4+ T cells, while they had enhanced Th2 polarization. TRIM24-knockout CD4+ T cells had decreased acetylation of STAT6 and enhanced STAT6 activities after IL-4 stimulation. The regulation of STAT6 activities by TRIM24 depended on TRIM24 N terminal RIGN domain and Lys383 acetylation site of STAT6.

Conclusions: TRIM24 suppresses Th2-mediated AR by regulating the acetylation of STAT6.

目的:变应性鼻炎(AR)是一种辅助性T细胞2型(Th2)介导的炎症性疾病。含有24的E3连接酶三重基序(TRIM24)调节乙酰转移酶CREB结合蛋白(CBP)向信号转导子和转录激活子6(STAT6)的募集。CBP介导STAT6的乙酰化并降低其活性。迄今为止,TRIM24在AR中的确切作用尚未得到充分解释。本研究旨在探讨TRIM24在AR中的作用。方法:检测AR患者外周血单个核细胞(PBMC)和CD4+T细胞中TRIM24的表达。产生CD4+T细胞中具有TRIM24缺陷的TRIM24条件敲除小鼠。建立了宽型(WT)AR小鼠和TRIM24条件性敲除AR小鼠。然后比较AR症状和白细胞介素-4水平。此外,测定了刺激后来自WT小鼠和TRIM24敲除小鼠的CD4+T细胞的增殖、活化和极化。还评估了TRIM24缺乏对STAT6活性的影响。结果:在AR患者的PBMC和CD4+T细胞中检测到下调的TRIM24表达。TRIM24条件敲除小鼠的AR症状更严重,IL-4产生增加。与WT CD4+T细胞相比,TRIM24敲除的CD4+T淋巴细胞具有相似的增殖和活化,同时它们具有增强的Th2极化。TRIM24敲除CD4+T细胞在IL-4刺激后降低了STAT6的乙酰化并增强了STAT6活性。TRIM24对STAT6活性的调节依赖于TRIM24 N末端RIGN结构域和STAT6的Lys383乙酰化位点。结论:TRIM24通过调节STAT6的乙酰化来抑制Th2介导的AR。
{"title":"TRIM24-Mediated Acetylation of STAT6 Suppresses Th2-Induced Allergic Rhinitis.","authors":"Liyan Yue,&nbsp;Qiaojing Jia,&nbsp;Jinhui Dong,&nbsp;Jianxing Wang,&nbsp;Xiumin Ren,&nbsp;Ou Xu","doi":"10.4168/aair.2023.15.5.603","DOIUrl":"10.4168/aair.2023.15.5.603","url":null,"abstract":"<p><strong>Purpose: </strong>Allergic rhinitis (AR) is a T helper type 2 (Th2)-mediated inflammatory disease. The E3 ligase tripartite motif-containing 24 (TRIM24) regulates the recruitment of acetyltransferase CREB-binding protein (CBP) to signal transducer and activator of transcription 6 (STAT6). CBP mediates the acetylation of STAT6 and decreases its activity. To date, the precise role of TRIM24 in AR has not been fully interpreted. Herein, our study aimed to explore the functions of TRIM24 in AR.</p><p><strong>Methods: </strong>The expression of TRIM24 in peripheral blood mononuclear cells (PBMCs) and CD4<sup>+</sup> T cells from patients with AR was measured. TRIM24-conditional knockout mice with TRIM24 deficiency in CD4<sup>+</sup> T cells were generated. Wide-type (WT) AR mice and TRIM24-conditional knockout AR mice were established. Then, AR symptoms and interleukin (IL)-4 levels were compared. Further, the proliferation, activation and polarization of CD4<sup>+</sup> T cells from WT mice and TRIM24 knockout mice after stimulation were determined. The effects of TRIM24 deficiency on STAT6 activities were also evaluated.</p><p><strong>Results: </strong>Downregulated TRIM24 expression was detected in PBMCs and CD4<sup>+</sup> T cells from patients with AR. TRIM24 conditional knockout mice had more sever AR symptoms with elevated IL-4 production. TRIM24-knockout CD4<sup>+</sup> T cells had similar proliferation and activation when compared to WT CD4<sup>+</sup> T cells, while they had enhanced Th2 polarization. TRIM24-knockout CD4<sup>+</sup> T cells had decreased acetylation of STAT6 and enhanced STAT6 activities after IL-4 stimulation. The regulation of STAT6 activities by TRIM24 depended on TRIM24 N terminal RIGN domain and Lys383 acetylation site of STAT6.</p><p><strong>Conclusions: </strong>TRIM24 suppresses Th2-mediated AR by regulating the acetylation of STAT6.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 5","pages":"603-613"},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/b7/aair-15-603.PMC10570786.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41188260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Causal Link between Human Blood Metabolites and Asthma: An Investigation Using Mendelian Randomization 人类血液代谢物与哮喘之间的因果关系:孟德尔随机化研究
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-08-29 DOI: 10.29328/journal.aaai.1001032
Yong-Qing Zhu, Xiao-Yan Meng, Jing-Hua Yang
Background: Asthma, a chronic inflammatory respiratory ailment, is characterized by variable airflow obstruction and heightened bronchial reactivity. Despite therapeutic advancements, a comprehensive comprehension of its underlying metabolic mechanisms remains elusive. Metabolomics has emerged as a powerful approach to investigating the complex connections between serum metabolites and disease pathogenesis. However, exploring the causal relationship between serum metabolites and asthma susceptibility demands meticulous examination to unveil potential therapeutic targets. Methods: Mendelian randomization (MR) approach was explored to investigate the potential causal associations between serum metabolites and asthma risk. The main analysis employed the inverse variance weighted method, supported by supplementary approaches such as MR-Egger, weighted median, weighted mode, and sample mode. To enhance the strength and credibility of our results, we conducted sensitivity analyses encompassing heterogeneity testing, assessment of horizontal pleiotropy, and leave-one-out analysis. Additionally, pathway enrichment analysis was performed to further elucidate the results. Results: We identified 18 known and 12 unknown metabolites with potential associations with asthma risk. Among known metabolites, seven exhibited protective effects (e.g., 4-acetamidobutanoate, allantoin, kynurenine, oxidized bilirubin*), while eleven were considered risk factors (e.g., ornithine, N-acetylornithine, alanine). Through the integration of four additional MR models and sensitivity analyses, we revealed a connection between 4-acetamidobutanoate and approximately 6% lower asthma risk (OR = 0.94, 95% CI: 0.90–0.98). Conclusions: Our MR analysis uncovered protective and risk-associated metabolites, alongside 12 unknown metabolites linked to asthma. Notably, 4-acetamidobutanoate demonstrated a nominal 6% reduction in asthma risk, highlighting its potential significance.
背景:哮喘是一种慢性炎症性呼吸道疾病,其特征是可变气流阻塞和支气管反应性增高。尽管治疗取得了进步,但对其潜在代谢机制的全面理解仍然难以捉摸。代谢组学已成为研究血清代谢物与疾病发病机制之间复杂联系的有力方法。然而,探索血清代谢物与哮喘易感性之间的因果关系需要细致的检查,以揭示潜在的治疗靶点。方法:采用孟德尔随机化方法探讨血清代谢物与哮喘风险之间的潜在因果关系。分析主要采用方差反加权法,辅以MR-Egger、加权中位数、加权众数、样本众数等方法。为了提高结果的强度和可信度,我们进行了敏感性分析,包括异质性测试、水平多效性评估和遗漏分析。此外,还进行了途径富集分析以进一步阐明结果。结果:我们确定了18种已知代谢物和12种未知代谢物与哮喘风险的潜在关联。在已知的代谢物中,有7种具有保护作用(如4-乙酰氨基丁酸酯、尿囊素、犬尿氨酸、氧化胆红素*),而11种被认为是危险因素(如鸟氨酸、n -乙酰鸟氨酸、丙氨酸)。通过整合另外四个MR模型和敏感性分析,我们揭示了4-乙酰氨基丁酸盐与哮喘风险降低约6%之间的联系(OR = 0.94, 95% CI: 0.90-0.98)。结论:我们的MR分析揭示了保护性和风险相关的代谢物,以及12种与哮喘相关的未知代谢物。值得注意的是,4-乙酰氨基丁酸酯显示哮喘风险降低6%,突出了其潜在意义。
{"title":"Causal Link between Human Blood Metabolites and Asthma: An Investigation Using Mendelian Randomization","authors":"Yong-Qing Zhu, Xiao-Yan Meng, Jing-Hua Yang","doi":"10.29328/journal.aaai.1001032","DOIUrl":"https://doi.org/10.29328/journal.aaai.1001032","url":null,"abstract":"Background: Asthma, a chronic inflammatory respiratory ailment, is characterized by variable airflow obstruction and heightened bronchial reactivity. Despite therapeutic advancements, a comprehensive comprehension of its underlying metabolic mechanisms remains elusive. Metabolomics has emerged as a powerful approach to investigating the complex connections between serum metabolites and disease pathogenesis. However, exploring the causal relationship between serum metabolites and asthma susceptibility demands meticulous examination to unveil potential therapeutic targets. Methods: Mendelian randomization (MR) approach was explored to investigate the potential causal associations between serum metabolites and asthma risk. The main analysis employed the inverse variance weighted method, supported by supplementary approaches such as MR-Egger, weighted median, weighted mode, and sample mode. To enhance the strength and credibility of our results, we conducted sensitivity analyses encompassing heterogeneity testing, assessment of horizontal pleiotropy, and leave-one-out analysis. Additionally, pathway enrichment analysis was performed to further elucidate the results. Results: We identified 18 known and 12 unknown metabolites with potential associations with asthma risk. Among known metabolites, seven exhibited protective effects (e.g., 4-acetamidobutanoate, allantoin, kynurenine, oxidized bilirubin*), while eleven were considered risk factors (e.g., ornithine, N-acetylornithine, alanine). Through the integration of four additional MR models and sensitivity analyses, we revealed a connection between 4-acetamidobutanoate and approximately 6% lower asthma risk (OR = 0.94, 95% CI: 0.90–0.98). Conclusions: Our MR analysis uncovered protective and risk-associated metabolites, alongside 12 unknown metabolites linked to asthma. Notably, 4-acetamidobutanoate demonstrated a nominal 6% reduction in asthma risk, highlighting its potential significance.","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"110 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81578558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive Significance of Claudin-3 for Epithelial Barrier Dysfunction in Chronic Rhinosinusitis With Nasal Polyps. Claudin-3对慢性鼻窦炎伴鼻息肉患者上皮屏障功能障碍的预测意义。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-07-01 DOI: 10.4168/aair.2023.15.4.512
Zhi-Qun Huang, Jing Ye, Jing Liu, Li-Ying Sun, Hsiao Hui Ong, Yong-Hao Wei, Shu-Cai Fu, Xiao-Xun Hu, Yu Xu, De-Yun Wang

Purpose: The abnormal expression of tight junction (TJ) plays a vital role in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). However, there is no appropriate tool to distinguish and diagnose epithelial barrier defects in clinical practice. This study aimed to evaluate the predictive value of claudin-3 for epithelial barrier dysfunction in CRSwNP.

Methods: In this study, TJ protein levels were evaluated by real-time quantitative polymerase chain reaction, immunofluorescent, and immunohistochemistry staining in control subjects and CRSwNP patients. The receiver operating characteristic (ROC) curve was created to assess the predictive value of TJ breakdown in clinical outcomes. In vitro, human nasal epithelial cells were cultured at the air-liquid interface to analyze the transepithelial electrical resistance (TER) level.

Results: The expression levels of occludin, tricellulin, claudin-3, and claudin-10 were decreased (all P < 0.05), and those of claudin-1 was increased (P < 0.05) in CRSwNP patients as compared to healthy subjects. Additionally, claudin-3 and occludin levels were negatively correlated with the computed tomography score in CRSwNP (all P < 0.05), and the ROC curve indicated that the claudin-3 level had the most predictive accuracy in evaluating epithelial barrier disruption (area under the curve = 0.791, P < 0.001). Finally, the time-series analysis showed the highest correlation coefficient between TER and claudin-3 (cross-correlation function = 0.75).

Conclusion: In this study, we suggest that claudin-3 could be a valuable biomarker for predicting nasal epithelial barrier defects and disease severity in CRSwNP.

目的:紧密连接蛋白(tight junction, TJ)的异常表达在慢性鼻窦炎伴鼻息肉(CRSwNP)的发病过程中起着至关重要的作用。然而,在临床实践中,没有合适的工具来区分和诊断上皮屏障缺陷。本研究旨在评估claudin-3对CRSwNP中上皮屏障功能障碍的预测价值。方法:本研究采用实时定量聚合酶链反应、免疫荧光和免疫组织化学染色检测对照组和CRSwNP患者的TJ蛋白水平。建立受试者工作特征(ROC)曲线,评价TJ分解对临床预后的预测价值。体外培养人鼻上皮细胞,测定其经皮电阻(TER)水平。结果:CRSwNP患者occludin、tricellulin、claudin-3、claudin-10的表达水平较健康者降低(P < 0.05), claudin-1表达水平较健康者升高(P < 0.05)。此外,claudin-3和occludin水平与CRSwNP的计算机断层扫描评分呈负相关(均P < 0.05), ROC曲线显示claudin-3水平在评估上皮屏障破坏方面具有最高的预测准确性(曲线下面积= 0.791,P < 0.001)。最后,时间序列分析显示,TER与claudin-3的相关系数最高(互相关函数= 0.75)。结论:在本研究中,我们提示cludin -3可能是预测CRSwNP患者鼻上皮屏障缺陷和疾病严重程度的有价值的生物标志物。
{"title":"Predictive Significance of Claudin-3 for Epithelial Barrier Dysfunction in Chronic Rhinosinusitis With Nasal Polyps.","authors":"Zhi-Qun Huang,&nbsp;Jing Ye,&nbsp;Jing Liu,&nbsp;Li-Ying Sun,&nbsp;Hsiao Hui Ong,&nbsp;Yong-Hao Wei,&nbsp;Shu-Cai Fu,&nbsp;Xiao-Xun Hu,&nbsp;Yu Xu,&nbsp;De-Yun Wang","doi":"10.4168/aair.2023.15.4.512","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.512","url":null,"abstract":"<p><strong>Purpose: </strong>The abnormal expression of tight junction (TJ) plays a vital role in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). However, there is no appropriate tool to distinguish and diagnose epithelial barrier defects in clinical practice. This study aimed to evaluate the predictive value of claudin-3 for epithelial barrier dysfunction in CRSwNP.</p><p><strong>Methods: </strong>In this study, TJ protein levels were evaluated by real-time quantitative polymerase chain reaction, immunofluorescent, and immunohistochemistry staining in control subjects and CRSwNP patients. The receiver operating characteristic (ROC) curve was created to assess the predictive value of TJ breakdown in clinical outcomes. <i>In vitro,</i> human nasal epithelial cells were cultured at the air-liquid interface to analyze the transepithelial electrical resistance (TER) level.</p><p><strong>Results: </strong>The expression levels of occludin, tricellulin, claudin-3, and claudin-10 were decreased (all <i>P</i> < 0.05), and those of claudin-1 was increased (<i>P</i> < 0.05) in CRSwNP patients as compared to healthy subjects. Additionally, claudin-3 and occludin levels were negatively correlated with the computed tomography score in CRSwNP (all <i>P</i> < 0.05), and the ROC curve indicated that the claudin-3 level had the most predictive accuracy in evaluating epithelial barrier disruption (area under the curve = 0.791, <i>P</i> < 0.001). Finally, the time-series analysis showed the highest correlation coefficient between TER and claudin-3 (cross-correlation function = 0.75).</p><p><strong>Conclusion: </strong>In this study, we suggest that claudin-3 could be a valuable biomarker for predicting nasal epithelial barrier defects and disease severity in CRSwNP.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"512-525"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/70/aair-15-512.PMC10359644.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9852534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Efficacy of Second-Line Treatments in Chronic Urticaria Refractory to Standard Dose Antihistamines. 二线治疗标准剂量抗组胺药难治性慢性荨麻疹的疗效观察。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-07-01 DOI: 10.4168/aair.2023.15.4.496
Mi-Ae Kim, Jeong-Hee Choi, Yoo-Seob Shin, Hae-Sim Park, Young-Min Ye

Purpose: The prevalence of chronic urticaria (CU) is increasing worldwide, and it imposes a major burden on patients. Few studies have evaluated the efficacy of second-line treatments of CU, particularly for patients being considered for costly third-line treatments such as omalizumab. We compared the efficacy and safety of second-line treatments of CU refractory to standard doses of nonsedating H1-antihistamines (nsAHs).

Methods: This 4-week, prospective, randomized, open-label trial divided patients into 4 treatment groups: 4-fold updosing of nsAHs, multiple combination of 4 nsAHs, switching to other nsAHs, and adjunctive H2-receptor antagonist. The clinical outcomes included urticaria control status, symptoms, and rescue medication use.

Results: This study included 109 patients. After 4 weeks of second-line treatment, urticaria was well-controlled, partly controlled, and uncontrolled in 43.1%, 36.7%, and 20.2% of patients, respectively. Complete control of CU was achieved in 20.4% of patients. Among the patients with high-dose nsAHs, the proportion with well-controlled status was higher compared to the patients who received standard doses (51.9% vs. 34.5%, P = 0.031). No significant difference was observed in the proportion of well-controlled cases between the updosing and combination treatment groups (57.7% vs. 46.4%, P = 0.616). However, increasing the dose of nsAHs 4-fold was associated with a higher rate of complete symptom control compared to multiple combination treatment with 4 nsAHs (40.0% vs. 10.7%, P = 0.030). Logistic regression analysis confirmed the higher efficacy of updosing of nsAHs for complete control of CU compared to the other treatment strategies (odds ratio, 0.180; P = 0.020).

Conclusions: In patients with CU refractory to standard doses of nsAHs, both updosing of nsAHs 4-fold and multiple combination treatment with 4 nsAHs increased the rate of well-controlled cases without causing significant adverse effects. Updosing of nsAHs is more effective for complete CU control than combination treatment.

目的:慢性荨麻疹(CU)的患病率在全球范围内呈上升趋势,给患者带来了沉重的负担。很少有研究评估CU二线治疗的疗效,特别是考虑接受昂贵的三线治疗(如omalizumab)的患者。我们比较了难治CU的二线治疗与标准剂量非镇静h1 -抗组胺药(nsAHs)的疗效和安全性。方法:这项为期4周的前瞻性、随机、开放标签试验将患者分为4个治疗组:4倍增加nsAHs, 4种nsAHs的多重联合,切换到其他nsAHs,以及辅助h2受体拮抗剂。临床结果包括荨麻疹控制状况、症状和抢救用药情况。结果:本研究纳入109例患者。经过4周的二线治疗,分别有43.1%、36.7%和20.2%的患者荨麻疹得到良好控制、部分控制和未控制。20.4%的患者CU得到完全控制。在高剂量nsAHs患者中,控制良好的比例高于接受标准剂量的患者(51.9% vs. 34.5%, P = 0.031)。两组对照良好的病例比例差异无统计学意义(57.7% vs 46.4%, P = 0.616)。然而,与4种nsAHs的多重联合治疗相比,将nsAHs剂量增加4倍与更高的完全症状控制率相关(40.0%比10.7%,P = 0.030)。Logistic回归分析证实,与其他治疗策略相比,增加nsAHs剂量完全控制CU的疗效更高(优势比,0.180;P = 0.020)。结论:在标准剂量非甾体类药物难治性CU患者中,非甾体类药物4倍加药和4种非甾体类药物多次联合治疗均可增加控制良好病例的发生率,且无明显不良反应。与联合治疗相比,增加nsAHs对完全控制CU更有效。
{"title":"Efficacy of Second-Line Treatments in Chronic Urticaria Refractory to Standard Dose Antihistamines.","authors":"Mi-Ae Kim,&nbsp;Jeong-Hee Choi,&nbsp;Yoo-Seob Shin,&nbsp;Hae-Sim Park,&nbsp;Young-Min Ye","doi":"10.4168/aair.2023.15.4.496","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.496","url":null,"abstract":"<p><strong>Purpose: </strong>The prevalence of chronic urticaria (CU) is increasing worldwide, and it imposes a major burden on patients. Few studies have evaluated the efficacy of second-line treatments of CU, particularly for patients being considered for costly third-line treatments such as omalizumab. We compared the efficacy and safety of second-line treatments of CU refractory to standard doses of nonsedating H<sub>1</sub>-antihistamines (nsAHs).</p><p><strong>Methods: </strong>This 4-week, prospective, randomized, open-label trial divided patients into 4 treatment groups: 4-fold updosing of nsAHs, multiple combination of 4 nsAHs, switching to other nsAHs, and adjunctive H<sub>2</sub>-receptor antagonist. The clinical outcomes included urticaria control status, symptoms, and rescue medication use.</p><p><strong>Results: </strong>This study included 109 patients. After 4 weeks of second-line treatment, urticaria was well-controlled, partly controlled, and uncontrolled in 43.1%, 36.7%, and 20.2% of patients, respectively. Complete control of CU was achieved in 20.4% of patients. Among the patients with high-dose nsAHs, the proportion with well-controlled status was higher compared to the patients who received standard doses (51.9% vs. 34.5%, <i>P</i> = 0.031). No significant difference was observed in the proportion of well-controlled cases between the updosing and combination treatment groups (57.7% vs. 46.4%, <i>P</i> = 0.616). However, increasing the dose of nsAHs 4-fold was associated with a higher rate of complete symptom control compared to multiple combination treatment with 4 nsAHs (40.0% vs. 10.7%, <i>P</i> = 0.030). Logistic regression analysis confirmed the higher efficacy of updosing of nsAHs for complete control of CU compared to the other treatment strategies (odds ratio, 0.180; <i>P</i> = 0.020).</p><p><strong>Conclusions: </strong>In patients with CU refractory to standard doses of nsAHs, both updosing of nsAHs 4-fold and multiple combination treatment with 4 nsAHs increased the rate of well-controlled cases without causing significant adverse effects. Updosing of nsAHs is more effective for complete CU control than combination treatment.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"496-511"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/92/aair-15-496.PMC10359646.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9854680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tissue Inhibitor of Metalloproteinase-1 Enhances Eosinophilic Airway Inflammation in Severe Asthma. 组织金属蛋白酶抑制剂-1 能增强严重哮喘患者的嗜酸性粒细胞气道炎症。
IF 4.1 2区 医学 Q2 ALLERGY Pub Date : 2023-07-01 Epub Date: 2023-02-28 DOI: 10.4168/aair.2023.15.4.451
Thi Bich Tra Cao, Quang Luu Quoc, Eun-Mi Yang, Ji-Young Moon, Yoo Seob Shin, Min Sook Ryu, Youngwoo Choi, Hae-Sim Park

Purpose: Severe asthma (SA) is characterized by persistent airway inflammation and remodeling, followed by lung function decline. The present study aimed to evaluate the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the pathogenesis of SA.

Methods: We enrolled 250 adult asthmatics (54 with SA and 196 with non-SA) and 140 healthy controls (HCs). Serum TIMP-1 levels were determined by enzyme-linked immunosorbent assay. The release of TIMP-1 from airway epithelial cells (AECs) in response to stimuli as well as the effects of TIMP-1 on the activations of eosinophils and macrophages were evaluated in vitro and in vivo.

Results: Significantly higher levels of serum TIMP-1 were noted in asthmatics than in HCs, in the SA group than in non-SA group, and in the type 2 SA group than in non-type 2 SA group (P < 0.01 for all). A negative correlation between serum TIMP-1 and FEV1% values (r = -0.400, P = 0.003) was noted in the SA group. In vitro study demonstrated that TIMP-1 was released from AECs in response to poly I:C, IL-13, eosinophil extracellular traps (EETs) and in coculture with eosinophils. TIMP-1-stimulated mice showed eosinophilic airway inflammation, which was not completely suppressed by steroid treatment. In vitro and in vivo functional studies showed that TIMP-1 directly activated eosinophils and macrophages, and induced the release of EETs and macrophages to polarize toward M2 subset, which was suppressed by anti-TIMP-1 antibody.

Conclusions: These findings suggest that TIMP-1 enhances eosinophilic airway inflammation and that serum TIMP-1 may be a potential biomarker and/or therapeutic target for type 2 SA.

目的:重症哮喘(SA)的特征是持续的气道炎症和重塑,随后肺功能下降。本研究旨在评估组织金属蛋白酶抑制剂-1(TIMP-1)在哮喘发病机制中的作用:我们招募了 250 名成年哮喘患者(54 名 SA 患者和 196 名非 SA 患者)和 140 名健康对照组(HCs)。血清 TIMP-1 水平通过酶联免疫吸附试验测定。在体外和体内评估了气道上皮细胞(AECs)在刺激下释放 TIMP-1 的情况以及 TIMP-1 对嗜酸性粒细胞和巨噬细胞活化的影响:哮喘患者的血清 TIMP-1 水平明显高于 HCs,SA 组高于非 SA 组,2 型 SA 组高于非 2 型 SA 组(P 均<0.01)。在 SA 组中,血清 TIMP-1 与 FEV1% 值呈负相关(r = -0.400,P = 0.003)。体外研究表明,在聚 I:C、IL-13、嗜酸性粒细胞胞外捕获物(EETs)以及与嗜酸性粒细胞共培养的情况下,AECs 会释放 TIMP-1。受 TIMP-1 刺激的小鼠表现出嗜酸性粒细胞气道炎症,类固醇治疗并不能完全抑制这种炎症。体外和体内功能研究表明,TIMP-1 可直接激活嗜酸性粒细胞和巨噬细胞,并诱导 EETs 的释放和巨噬细胞向 M2 亚群极化,抗 TIMP-1 抗体可抑制这种极化:这些研究结果表明,TIMP-1 可增强嗜酸性粒细胞气道炎症,血清 TIMP-1 可能是 2 型 SA 的潜在生物标记物和/或治疗靶点。
{"title":"Tissue Inhibitor of Metalloproteinase-1 Enhances Eosinophilic Airway Inflammation in Severe Asthma.","authors":"Thi Bich Tra Cao, Quang Luu Quoc, Eun-Mi Yang, Ji-Young Moon, Yoo Seob Shin, Min Sook Ryu, Youngwoo Choi, Hae-Sim Park","doi":"10.4168/aair.2023.15.4.451","DOIUrl":"10.4168/aair.2023.15.4.451","url":null,"abstract":"<p><strong>Purpose: </strong>Severe asthma (SA) is characterized by persistent airway inflammation and remodeling, followed by lung function decline. The present study aimed to evaluate the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the pathogenesis of SA.</p><p><strong>Methods: </strong>We enrolled 250 adult asthmatics (54 with SA and 196 with non-SA) and 140 healthy controls (HCs). Serum TIMP-1 levels were determined by enzyme-linked immunosorbent assay. The release of TIMP-1 from airway epithelial cells (AECs) in response to stimuli as well as the effects of TIMP-1 on the activations of eosinophils and macrophages were evaluated <i>in vitro</i> and <i>in vivo</i>.</p><p><strong>Results: </strong>Significantly higher levels of serum TIMP-1 were noted in asthmatics than in HCs, in the SA group than in non-SA group, and in the type 2 SA group than in non-type 2 SA group (<i>P</i> < 0.01 for all). A negative correlation between serum TIMP-1 and FEV<sub>1</sub>% values (<i>r</i> = -0.400, <i>P</i> = 0.003) was noted in the SA group. <i>In vitro</i> study demonstrated that TIMP-1 was released from AECs in response to poly I:C, IL-13, eosinophil extracellular traps (EETs) and in coculture with eosinophils. TIMP-1-stimulated mice showed eosinophilic airway inflammation, which was not completely suppressed by steroid treatment. <i>In vitro</i> and <i>in vivo</i> functional studies showed that TIMP-1 directly activated eosinophils and macrophages, and induced the release of EETs and macrophages to polarize toward M2 subset, which was suppressed by anti-TIMP-1 antibody.</p><p><strong>Conclusions: </strong>These findings suggest that TIMP-1 enhances eosinophilic airway inflammation and that serum TIMP-1 may be a potential biomarker and/or therapeutic target for type 2 SA.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"451-472"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/93/aair-15-451.PMC10359643.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9857133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory Endotypes of Chronic Rhinosinusitis in the Korean Population: Distinct Expression of Type 3 Inflammation. 韩国人群慢性鼻窦炎的炎症内分型:3型炎症的独特表达。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-07-01 DOI: 10.4168/aair.2023.15.4.437
Jin-Young Min, Jin Youp Kim, Chung Man Sung, Seon Tae Kim, Hyun-Jin Cho, Sue Jean Mun, Sung-Woo Cho, Sang Duk Hong, Gwanghui Ryu, Kyoung Rai Cho, Young Hyo Kim, Soo Kyoung Park, Dong-Kyu Kim, Dong Hoon Lee, Sung Jae Heo, Ki-Il Lee, Su Jin Kim, Sangjun Lee, Ji-Hun Mo, Seung-Heon Shin, Dae Woo Kim

Purpose: Cluster analyses on inflammatory markers of chronic rhinosinusitis (CRS) in Asians from multicenter data are lacking. This multicenter study aimed to identify the endotypes of CRS in Koreans and to evaluate the relationship between the endotypes and clinical parameters.

Methods: Nasal tissues were obtained from patients with CRS and controls who underwent surgery. The endotypes of CRS were investigated by measuring interleukin (IL)-5, interferon (IFN)-γ, IL-17A, IL-22, IL-1β, IL-6, IL-8, matrix metalloproteinase-9, eotaxin-3, eosinophil cationic protein, myeloperoxidase (MPO), human neutrophil elastase (HNE), periostin, transforming growth factor-β1, total immunoglobulin E (IgE), and staphylococcal enterotoxin (SE)-specific IgE. We performed hierarchical cluster analysis and evaluated the phenotype, comorbidities, and Lund-Mackay computed tomography (LM CT) score in each cluster.

Results: Five clusters and 3 endotypes were extracted from 244 CRS patients: cluster 1 had no upregulated mediators compared to the other clusters (mild mixed inflammatory CRS); clusters 2, 3, and 4 had higher concentrations of neutrophil-associated mediators including HNE, IL-8, IL-17A, and MPO (T3 CRS); and cluster 5 had higher levels of eosinophil-associated mediators (T2 CRS). SE-specific IgE was undetectable in T3 CRS and had low detectable levels (6.2%) even in T2 CRS. The CRS with nasal polyps (CRSwNP) phenotype and LM CT scores showed no significant differences between T2 and T3 CRS, while the incidence of comorbid asthma was higher in T2 CRS than T3 CRS. In T3 clusters, higher levels of neutrophilic markers were associated with disease severity and CRSwNP phenotype.

Conclusions: In Koreans, there is a distinct T3 CRS endotype showing a high proportion of CRSwNP and severe disease extent, along with T2 CRS.

目的:缺乏来自亚洲人慢性鼻窦炎(CRS)多中心数据的炎症标志物聚类分析。这项多中心研究旨在确定韩国人CRS的内型,并评估内型与临床参数之间的关系。方法:从CRS患者和接受手术的对照组中获得鼻腔组织。采用白细胞介素(IL)-5、干扰素(IFN)-γ、IL- 17a、IL-22、IL-1β、IL-6、IL-8、基质金属蛋白酶-9、eotaxin-3、嗜酸性阳离子蛋白、髓过氧化物酶(MPO)、人中性粒细胞弹性酶(HNE)、骨膜蛋白、转化生长因子-β1、总免疫球蛋白E (IgE)、葡萄球菌肠毒素(SE)特异性IgE检测CRS的内源性类型。我们进行了分层聚类分析,并评估了每个聚类的表型、合并症和隆德-麦凯计算机断层扫描(LM CT)评分。结果:从244例CRS患者中提取了5个簇和3种内型:与其他簇(轻度混合炎性CRS)相比,簇1没有上调的介质;集群2、3和4具有较高浓度的中性粒细胞相关介质,包括HNE、IL-8、IL-17A和MPO (T3 CRS);第5类患者嗜酸性粒细胞相关介质(T2 CRS)水平较高。se特异性IgE在T3 CRS中检测不到,即使在T2 CRS中也有较低的检测水平(6.2%)。伴有鼻息肉的CRS (CRSwNP)表型和LM CT评分在T2和T3 CRS之间无显著差异,但T2 CRS的共病哮喘发生率高于T3 CRS。在T3集群中,较高水平的中性粒细胞标记物与疾病严重程度和CRSwNP表型相关。结论:韩国人存在明显的T3 CRS内型,CRSwNP比例高,疾病程度严重,T2 CRS也是如此。
{"title":"Inflammatory Endotypes of Chronic Rhinosinusitis in the Korean Population: Distinct Expression of Type 3 Inflammation.","authors":"Jin-Young Min,&nbsp;Jin Youp Kim,&nbsp;Chung Man Sung,&nbsp;Seon Tae Kim,&nbsp;Hyun-Jin Cho,&nbsp;Sue Jean Mun,&nbsp;Sung-Woo Cho,&nbsp;Sang Duk Hong,&nbsp;Gwanghui Ryu,&nbsp;Kyoung Rai Cho,&nbsp;Young Hyo Kim,&nbsp;Soo Kyoung Park,&nbsp;Dong-Kyu Kim,&nbsp;Dong Hoon Lee,&nbsp;Sung Jae Heo,&nbsp;Ki-Il Lee,&nbsp;Su Jin Kim,&nbsp;Sangjun Lee,&nbsp;Ji-Hun Mo,&nbsp;Seung-Heon Shin,&nbsp;Dae Woo Kim","doi":"10.4168/aair.2023.15.4.437","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.437","url":null,"abstract":"<p><strong>Purpose: </strong>Cluster analyses on inflammatory markers of chronic rhinosinusitis (CRS) in Asians from multicenter data are lacking. This multicenter study aimed to identify the endotypes of CRS in Koreans and to evaluate the relationship between the endotypes and clinical parameters.</p><p><strong>Methods: </strong>Nasal tissues were obtained from patients with CRS and controls who underwent surgery. The endotypes of CRS were investigated by measuring interleukin (IL)-5, interferon (IFN)-γ, IL-17A, IL-22, IL-1β, IL-6, IL-8, matrix metalloproteinase-9, eotaxin-3, eosinophil cationic protein, myeloperoxidase (MPO), human neutrophil elastase (HNE), periostin, transforming growth factor-β1, total immunoglobulin E (IgE), and staphylococcal enterotoxin (SE)-specific IgE. We performed hierarchical cluster analysis and evaluated the phenotype, comorbidities, and Lund-Mackay computed tomography (LM CT) score in each cluster.</p><p><strong>Results: </strong>Five clusters and 3 endotypes were extracted from 244 CRS patients: cluster 1 had no upregulated mediators compared to the other clusters (mild mixed inflammatory CRS); clusters 2, 3, and 4 had higher concentrations of neutrophil-associated mediators including HNE, IL-8, IL-17A, and MPO (T3 CRS); and cluster 5 had higher levels of eosinophil-associated mediators (T2 CRS). SE-specific IgE was undetectable in T3 CRS and had low detectable levels (6.2%) even in T2 CRS. The CRS with nasal polyps (CRSwNP) phenotype and LM CT scores showed no significant differences between T2 and T3 CRS, while the incidence of comorbid asthma was higher in T2 CRS than T3 CRS. In T3 clusters, higher levels of neutrophilic markers were associated with disease severity and CRSwNP phenotype.</p><p><strong>Conclusions: </strong>In Koreans, there is a distinct T3 CRS endotype showing a high proportion of CRSwNP and severe disease extent, along with T2 CRS.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"437-450"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/b4/aair-15-437.PMC10359642.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9857134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Serum Zonulin Is a Biomarker for Severe Asthma. 血清Zonulin是重度哮喘的生物标志物。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-07-01 DOI: 10.4168/aair.2023.15.4.526
Na Young Kim, Eun Shin, Sun-Ju Byeon, Seok Jin Hong, Sung Hun Kang, Taehoon Lee, Tae-Bum Kim, Jeong-Hee Choi
Zonulin is a regulator of epithelial and endothelial barrier function. It regulates intestinal permeability through disrupting tight junctions. Defective epithelial barrier function is a hallmark of airway inflammation in asthma. This study aimed to investigate the role of zonulin in the pathogenesis of severe asthma. We enrolled 56 adult patients with asthma (29 severe asthma and 27 mild-to-moderate asthma) and 33 normal controls. The clinical data, sera, and lung tissues of the patients were provided by the Cohort for Reality and Evolution of adult Asthma in Korea (COREA) and the Biobank of Soonchunhyang University Bucheon Hospital, South Korea. Serum zonulin levels were estimated using an enzyme-linked immunosorbent assay, and zonulin expression in the bronchial tissue was evaluated by immunohistochemical staining. The serum zonulin levels were significantly higher in patients with severe asthma (51.98 ± 19.66 ng/mL) than in those with mild-to-moderate asthma and normal controls (26.35 ± 13.70 vs. 17.26 ± 10.29 ng/mL, P < 0.001). They significantly correlated with percent predicted forced expiratory volume in one second (%FEV1) (r = −0.35, P = 0.009). The zonulin expression in the bronchial epithelium was greater in patients with severe asthma. A serum zonulin cutoff value to distinguish between severe and mild-to-moderate asthmatics was 38.83 ng/mL. Zonulin may play an important role in the pathogenesis of severe asthma, and serum zonulin could be a potential biomarker for severe asthma.
Zonulin是上皮和内皮屏障功能的调节剂。它通过破坏紧密连接来调节肠道通透性。上皮屏障功能缺陷是哮喘气道炎症的标志。本研究旨在探讨zonulin在重症哮喘发病机制中的作用。我们招募了56名成年哮喘患者(29名重度哮喘患者和27名轻中度哮喘患者)和33名正常对照。患者的临床资料、血清和肺组织由韩国成人哮喘现实和进化队列(COREA)和韩国顺春香大学富川医院生物银行提供。使用酶联免疫吸附法估计血清中zonulin的水平,并通过免疫组织化学染色评估支气管组织中zonulin的表达。重度哮喘患者血清zonulin水平(51.98±19.66 ng/mL)明显高于轻中度哮喘和正常对照组(26.35±13.70 vs. 17.26±10.29 ng/mL, P < 0.001)。它们与预测一秒钟用力呼气量的百分比(%FEV1)显著相关(r = -0.35, P = 0.009)。支气管上皮zonulin的表达在严重哮喘患者中较高。区分重度和轻中度哮喘患者的血清带蛋白临界值为38.83 ng/mL。Zonulin可能在严重哮喘的发病机制中发挥重要作用,血清Zonulin可能是严重哮喘的潜在生物标志物。
{"title":"Serum Zonulin Is a Biomarker for Severe Asthma.","authors":"Na Young Kim,&nbsp;Eun Shin,&nbsp;Sun-Ju Byeon,&nbsp;Seok Jin Hong,&nbsp;Sung Hun Kang,&nbsp;Taehoon Lee,&nbsp;Tae-Bum Kim,&nbsp;Jeong-Hee Choi","doi":"10.4168/aair.2023.15.4.526","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.526","url":null,"abstract":"Zonulin is a regulator of epithelial and endothelial barrier function. It regulates intestinal permeability through disrupting tight junctions. Defective epithelial barrier function is a hallmark of airway inflammation in asthma. This study aimed to investigate the role of zonulin in the pathogenesis of severe asthma. We enrolled 56 adult patients with asthma (29 severe asthma and 27 mild-to-moderate asthma) and 33 normal controls. The clinical data, sera, and lung tissues of the patients were provided by the Cohort for Reality and Evolution of adult Asthma in Korea (COREA) and the Biobank of Soonchunhyang University Bucheon Hospital, South Korea. Serum zonulin levels were estimated using an enzyme-linked immunosorbent assay, and zonulin expression in the bronchial tissue was evaluated by immunohistochemical staining. The serum zonulin levels were significantly higher in patients with severe asthma (51.98 ± 19.66 ng/mL) than in those with mild-to-moderate asthma and normal controls (26.35 ± 13.70 vs. 17.26 ± 10.29 ng/mL, P < 0.001). They significantly correlated with percent predicted forced expiratory volume in one second (%FEV1) (r = −0.35, P = 0.009). The zonulin expression in the bronchial epithelium was greater in patients with severe asthma. A serum zonulin cutoff value to distinguish between severe and mild-to-moderate asthmatics was 38.83 ng/mL. Zonulin may play an important role in the pathogenesis of severe asthma, and serum zonulin could be a potential biomarker for severe asthma.","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"526-535"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/98/aair-15-526.PMC10359649.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9854682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Roles of Tissue Inhibitor of Metalloproteinase-1 in Severe Asthma. 金属蛋白酶-1组织抑制剂在重症哮喘中的作用。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2023-07-01 DOI: 10.4168/aair.2023.15.4.416
Sang-Heon Kim
https://e-aair.org A wide array of inflammatory cytokines and mediators play roles in immune response and chronic inflammation in severe asthma (SA). Monoclonal antibodies targeting some of these molecules have shown clinical efficacy in reducing exacerbations and improving asthma control in SA.1 While biologic treatments, including anti-type 2 (T2) cytokines, such as interleukin (IL)-5, IL-4, and IL-13, and epithelial cell-derived alarmin thymic stromal lymphopoietin (TSLP), are now available in the clinical practice, many SA patients remain uncontrolled even with these treatments. Thus, a new therapeutic approach is needed to modulate inflammatory responses, not fully abrogated with current standard care and available biologics.
{"title":"Roles of Tissue Inhibitor of Metalloproteinase-1 in Severe Asthma.","authors":"Sang-Heon Kim","doi":"10.4168/aair.2023.15.4.416","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.416","url":null,"abstract":"https://e-aair.org A wide array of inflammatory cytokines and mediators play roles in immune response and chronic inflammation in severe asthma (SA). Monoclonal antibodies targeting some of these molecules have shown clinical efficacy in reducing exacerbations and improving asthma control in SA.1 While biologic treatments, including anti-type 2 (T2) cytokines, such as interleukin (IL)-5, IL-4, and IL-13, and epithelial cell-derived alarmin thymic stromal lymphopoietin (TSLP), are now available in the clinical practice, many SA patients remain uncontrolled even with these treatments. Thus, a new therapeutic approach is needed to modulate inflammatory responses, not fully abrogated with current standard care and available biologics.","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"416-418"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/69/aair-15-416.PMC10359650.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9906439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Allergy, Asthma & Immunology Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1